| 1.64 0 (0%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.32  |
1-year : | 2.59 |
| Resists | First : | 1.98 |
Second : | 2.22 |
| Pivot price | 1.78 |
|||
| Supports | First : | 1.61 |
Second : | 1.33 |
| MAs | MA(5) : | 1.68 |
MA(20) : | 1.78 |
| MA(100) : | 1.96 |
MA(250) : | 1.98 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.4 |
D(3) : | 11.3 |
| RSI | RSI(14): 36.3 | |||
| 52-week | High : | 3.07 | Low : | 1.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CERS ] has closed above bottom band by 12.2%. Bollinger Bands are 30.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.71 - 1.72 | 1.72 - 1.73 |
| Low: | 1.59 - 1.6 | 1.6 - 1.61 |
| Close: | 1.62 - 1.64 | 1.64 - 1.66 |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Thu, 18 Apr 2024
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024 - Business Wire
Thu, 18 Apr 2024
Cerus Corporation (NASDAQ:CERS) is a favorite amongst institutional investors who own 64% - Yahoo Finance
Wed, 17 Apr 2024
Cerus Corp (CERS) Shows Strength: Stock Moves 5.8% Higher - Yahoo Movies UK
Sun, 14 Apr 2024
Short Interest in Cerus Co. (NASDAQ:CERS) Rises By 16.0% - MarketBeat
Fri, 12 Apr 2024
Cerus stock gains as Craig Hallum starts at Buy (NASDAQ:CERS) - Seeking Alpha
Tue, 19 Mar 2024
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System ... - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 181 (M) |
| Shares Float | 155 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 74.9 (%) |
| Shares Short | 5,880 (K) |
| Shares Short P.Month | 4,500 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.28 |
| Profit Margin | -24 % |
| Operating Margin | 2 % |
| Return on Assets (ttm) | -8 % |
| Return on Equity (ttm) | -61.8 % |
| Qtrly Rev. Growth | 6.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.86 |
| EBITDA (p.s.) | -0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -7.81 |
| PEG Ratio | 0 |
| Price to Book value | 5.65 |
| Price to Sales | 1.9 |
| Price to Cash Flow | -6.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|